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This phase II trial assessed the toxicity and efficacy of irinotecan plus docetaxel in cisplatin-pretreated oesophageal cancer. Irinotecan
160mgm
 2 plus docetaxel 65mgm
 2 once every 3 weeks led to severe myelosuppression in four patients, all of whom experienced
neutropenic fever. After amendment of this regimen, 24 patients (male/female¼18/6; median age¼58.5 years; ECOG performance
status 0/1/2¼9/11/4) with advanced oesophageal cancer (adenocarcinoma/epidermoid carcinoma¼13/11) received irinotecan
55mgm
 2 plus docetaxel 25mgm
 2 on days 1, 8 and 15 of a 28-day cycle. Serious adverse events occurred in five patients, one with
lethal outcome (pneumonia). Haematological toxicity X31 was rare, whereas nonhaematological toxicity X31 was noted in nine out
of 24 patients (asthenia in five patients, diarrhoea in three patients, nausea/emesis in two patients, constipation in one patient).
Median survival time was 26 (range 2–70) weeks. Response rate, assessed according to the WHO criteria, was 12.5% (95% CI 2.7–
32.4%); rate of disease stabilisation (partial remission and stable disease) was 33.3% (95% CI 15.6–55.3%) with a median duration of
18.5 (range 16–51) weeks. Although the nonhaematological toxicity proved to be considerable, weekly irinotecan plus docetaxel is
feasible and shows some activity in extensively pretreated patients with oesophageal cancer.
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Owing to early lymphogenic and haematogenous spread, most
patients with oesophageal cancer are diagnosed with advanced
disease. These patients receive multimodal treatment if the
tumour is deemed to be resectable, or systemic chemotherapy if
palliation is the goal. Cisplatin has been the mainstay of
chemotherapy and chemoradiotherapy protocols during the last
decade (Herskovic et al, 1992; Bleiberg et al, 1997). In case of
resistance to cisplatin-based therapy, no evidence-based recom-
mendations regarding second-line treatment exist, but many
patients ask for more than measures of best supportive care.
Thus, there is a need for tolerable and active protocols beyond
cisplatin-based therapy. Irinotecan and taxanes proved to induce
remissions in oesophageal cancer (Ilson et al, 1998, 1999) although
single-agent docetaxel revealed only moderate activity (Heath
et al, 2002). The combination of irinotecan and docetaxel has
been investigated in phase I studies in patients with pretreated
solid tumours (Adjei et al, 2000; Couteau et al, 2000).
The recommended phase II dose on this schedule was irinotecan
160mgm
 2 followed by docetaxel 65mgm
 2 administered every
3 weeks (Adjei et al, 2000). This phase II trial was designed to
assess the activity and toxicity of the combination of irinotecan
plus docetaxel in cisplatin-pretreated relapsed or refractory
oesophageal cancer.
METHODS
Patient population
Patients with histologically confirmed adenocarcinoma or epider-
moid carcinoma of the oesophagus were enrolled at a single site
(Klinikum rechts der Isar, Technical University of Munich).
Eligible patients with metastatic disease or locally advanced
disease not curable with surgery or radiation therapy were
previously treated with cisplatin-based chemotherapy or chemor-
adiotherapy. Patients were greater than 18 years of age with an
ECOG performance status p2.
Adequate bone marrow, renal and hepatic function was
necessary and was defined as an absolute neutrophil count
(ANC) X1500ml
 1, platelets X100000ml
 1, S-creatinine
o1.5 upper limit of normal (ULN), total bilirubin p1.5 
ULN, SGOT and/or SGPT p1.5 ULN (p5.0 ULN in the
presence of liver metastasis). Patients were not allowed to have
any CNS metastases, neuropathy Xgrade 2 and had to have a life
expectancy of X12 weeks.
Pretreatment evaluation included signed written informed
consent, complete history and physical examination, laboratory
tests, CT scans of all tumour involved areas, ECG and urine or
serum beta-HCG if the patient was a female of child-bearing age.
The study was approved by the ethics committee for human
research at the Technical University of Munich.
Treatment plan
Initially, irinotecan was administered at a dose of 160mgm
 2 over
90min immediately followed by docetaxel 65mgm
 2 over 60min Received 14 February 2003; accepted 25 May 2003
*Correspondence: Dr F Lordick; E-mail: f.lordick@lrz.tum.de
British Journal of Cancer (2003) 89, 630–633
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lonce every 3 weeks. One treatment every 3 weeks was considered
one cycle. This regimen was amended after the treatment of four
patients.
After the amendment, irinotecan was administered at a dose of
55mgm
 2 over 90min followed by docetaxel 25mgm
 2 over
60min on days 1, 8 and 15 of a 28-day cycle.
After two cycles of therapy, patients underwent follow-up CT
scans for assessment of response according to the WHO criteria.
Patients were seen every week in the outpatient clinic for
laboratory tests and evaluation of toxicity and adverse events.
Patients were treated until best response or until there was
evidence of progression of disease or increasing side effects.
Toxicity was graded using the NCI common toxicity criteria
(version 2.0).
Statistical considerations
The primary end point of the study was to determine the
proportion of patients who respond to irinotecan plus docetaxel.
The study was designed as a two-stage trial according to
Gehan (1961) assuming a response rate of 15%. With a power of
90%, this resulted in a sample size of 15 for the first stage.
The size of the second stage was determined by the observed
number of responses and by the prespecified precision of 10%. All
eligible patients were included in response, toxicity and survival
analyses.
RESULTS
Experiences with irinotecan plus docetaxel once every 3
weeks
Four male patients (median age 55 years, range 53–65 years;
ECOG performance status¼one in all four patients, pretreated
with cisplatinum-based combination chemotherapy in three
patients and by cisplatinum-based chemoradiotherapy in one
patient) were treated with irinotecan plus docetaxel once every 3
weeks. After four cycles administered in two patients and six cycles
given in two patients, two patients achieved a partial remission and
two patients had stable disease. All patients experienced febrile
neutropenia at least once. Neutropenia grade 3/4 was noted in all
18 cycles that were administered. Other grade 3/4 toxicities were
thrombocytopenia in one patient, anaemia in two patients,
hyponatraemia due to diarrhoea in one patient, hypoglycaemia
in one patient, nausea in one patient and asthenia in one patient.
Toxicity necessitated dose reductions and/or delay of therapy in all
patients. Mean irinotecan dose intensity (DI) of 45.4mgm
 2
week
 1 was 85.2% of the planned DI; mean docetaxel DI of
17.5mgm
 2 week
 1 was 80.6% of the planned DI. In order to
reduce the haematological toxicity, the chemotherapy regimen was
amended.
Patient characteristics, response and survival with
irinotecan and docetaxel 3 out of 4 weeks
After amendment of the study, from March 2001 to July 2002, 24
patients were enrolled. Patient characteristics are listed in Table 1.
Nine (37.5%) of the patients had undergone oesophagectomy, all
patients had received cisplatin-based chemotherapy or chemor-
adiotherapy or both. Lymph nodes, lung and liver were the
predominant sites of metastatic disease. In 11 patients (45.8%)
tumours had not responded on first-line chemotherapy or
chemoradiotherapy, whereas in 13 patients (54.2%) tumours
had relapsed or progressed after initial complete or partial
remission.
The patients completed a median of two cycles (range 0–4
cycles). In four patients, treatment was continued until best
response. In 14 patients, treatment was discontinued due to disease
progression. In six patients, adverse events or other medical
complications impeded further treatment.
In 20 patients, tumour response was evaluable according to the
WHO criteria. Four patients who did not complete two cycles were
evaluated as having progressive disease. There were no complete
responses. Three patients achieved a partial remission. The
response rate was 12.5% (95% CI¼2.7–32.4%). Overall, eight
patients (33.3%, 95% CI¼15.6–55.3%) had disease stabilisation
(partial remission or stable disease) with a median duration of 18.5
weeks (range 16–51). Interestingly, those patients who achieved
partial remission had a limited tumour burden with no more than
two organs involved (one patient with nodal involvement, one
patient with pulmonary involvement, one patient with nodal and
pulmonary involvement). In contrast, those patients with more
than two organs involved all experienced rapid disease progres-
sion. Of note, the three responders on irinotecan plus docetaxel
had not received more than one pretreatment (one patient
pretreated with chemotherapy, two patients pretreated with
chemoradiotherapy). In contrast, in the six patients with more
than one pretreatment (two patients after two chemotherapies,
four patients after chemotherapy and chemoradiotherapy), five
patients primarily progressed during treatment with irinotecan
plus docetaxel and only one patient achieved disease stabilisation,
which was of short duration (16 weeks). Response and disease
stabilisation was equally associated with the two histological
subtypes of oesophageal carcinoma.
The median survival time was 26 weeks (range 2–70). In
patients achieving disease stabilisation (partial remission or stable
disease), median survival (51 weeks) was more than thrice as high
compared to patients with progressive disease during chemother-
apy (15 weeks; P¼0.183, log-rank test). The Kaplan–Meier
survival curves are shown in Figure 1. The median progression-
free survival was 9 weeks (range 2–51). To date, eight of the 24
patients (33.3%) are alive with a follow-up of 21 months.
Table 1 Patient characteristics
Characteristics
Total number of patients N¼24
Median age 58.5 (40–75) years
Gender
Male 18
Female 6
ECOG performance status
PS 0 9
PS 1 11
PS 2 4
Histology
Adenocarcinoma 13
Epidermoid carcinoma 11
Previous treatment
Chemotherapy 15
Chemoradiotherapy 5
Chemotherapy and chemoradiotherapy 4
Sites of measurable disease
Lymph nodes 5
Lung 2
Liver 1
Oesophagus and lymph nodes 2
Oesophagus and lung 3
Oesophagus and liver 1
Lymph nodes and lung 3
Lymph nodes and bone 1
Lung and liver 1
Oesophagus and lymph nodes and liver 1
Oesophagus and lymph nodes and lung 1
Lymph nodes and liver and soft tissue 1
Oesophagus and lymph nodes and lung and liver 2
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After amendment of the study, the grade 3 and 4 toxicities
included neutropenia, asthenia, diarrhoea, nausea/emesis and
constipation (Table 2). Toxicity did not necessitate any dose
reductions. Serious adverse events occurred in five patients, one
with lethal outcome due to pneumonia. In contrast to the initial
schedule, no patient experienced febrile neutropenia with weekly
irinotecan plus docetaxel.
DISCUSSION
The object of this study was to assess the activity and toxicity of
irinotecan plus docetaxel in cisplatin-pretreated relapsed or
refractory oesophageal cancer. Irinotecan plus docetaxel adminis-
tered once every 3 weeks revealed unacceptable haematological
toxicity. Therefore, this regimen had to be amended. With weekly
irinotecan and docetaxel, which proved to be feasible, only 12.5%
of the patients achieved major remissions, but the study was
designed to obtain a response rate of at least 15.0%. Thus, at first
glance, this study yielded negative results regarding the end points
activity and toxicity. However, both end points deserve closer
attention.
The combination of irinotecan plus docetaxel administered once
every 3 weeks was established by two phase I studies published
recently (Adjei et al, 2000; Couteau et al, 2000). Both studies
enrolled patients with incurable cancer who had undergone at least
one prior chemotherapy or radiotherapy. In both phase I studies,
myelosuppression proved to be dose limiting. Therefore, not
surprisingly the four patients treated before the amendment of this
phase II study experienced neutropenia grade 3 or 4 with every
cycle. However, in contrast to the data from the phase I studies
indicating that febrile neutropenia occurred with a relatively low
incidence of 14 and 22.5%, respectively (Adjei et al, 2000; Couteau
et al, 2000), all four patients enrolled in this study required
hospitalisation due to febrile neutropenia at least once during their
treatment. The reasons for this unexpectedly high incidence rate of
severe haematological toxicity are not evident. Patients were not
older and their performance status was not worse compared to the
patients included into the two published phase I studies. However,
pretreatment of the oesophageal cancer patients enrolled into this
phase II trial was probably more myelotoxic compared to Adjei’s
study that included even some patients without prior chemother-
apy. Moreover, in our study no prophylactic growth factors were
allowed, which in contrast were administered in the two published
phase I studies. After this high complication rate became evident,
the protocol committee decided to amend the protocol. The
amendment took into account the dose intensity reached with 3-
weekly irinotecan plus docetaxel as well as previously published
data indicating a more favourable haematological toxicity profile,
if both docetaxel and irinotecan were given in weekly schedules
(Hainsworth et al, 1998; Murren et al, 2001). Indeed, with the
administration of irinotecan plus docetaxel 3 out of 4 weeks, a
dramatic decrease in myelosuppression was noted in comparison
to the initial schedule. No more febrile neutropenia occurred. On
the other hand, nonhaematological toxicity remained considerable.
Asthenia was the predominant side effect. This finding corre-
sponds with published data on protocols based on weekly
infusions of docetaxel (Hainsworth et al, 1998).
With an objective response rate of 12.5%, the activity of weekly
irinotecan plus docetaxel was lower than the 15.0% response rate
envisaged in this study. However, this result correlates well with
previous chemotherapy trials that have reported response rates of
6 and 0%, respectively, in patients with pretreated oesophageal
cancer (Conroy et al, 1996, Heath et al, 2002) and clearly indicates
the small likelihood of major remissions in cisplatin-pretreated
oesophageal cancer patients. Therefore, beside the response rate
one should also consider the rate of disease stabilisation indicating
a potential value of a treatment regimen within a phase II study.
With a rate of disease stabilisation of 33.3% (partial remissions
and stable diseases) and a median duration of 33.5 weeks (16–51
weeks), one can assume that this subset of patients derived some
benefit from this palliative treatment. This assumption is under-
lined by the notably longer median survival observed in the
patients with disease stabilisation compared to patients with
refractory disease. Of note, patients with a lower tumour burden
had a higher chance to achieve a partial remission, whereas those
patients with more than two organs involved all experienced early
disease progression. Although the small number of patients does
not justify any definite conclusions, this finding might influence
careful decision making for second-line treatment in oesophageal
cancer patients. Overall survival of the patients enrolled in this
study was short with a median duration of 26 weeks. However, this
was more than the median survival of 3.4 months reported in
oesophageal cancer patients treated with single-agent docetaxel
(Heath et al, 2002).
In conclusion, irinotecan plus docetaxel administered once
every 3 weeks as recommended previously revealed excessive
haematological toxicity and proved to be not feasible in the studied
patient population. In contrast, with the regimen of irinotecan plus
docetaxel 3 out of 4 weeks haematological toxicity was rather low.
Nonhaematological toxicity remained considerable but manage-
able. The activity of weekly irinotecan plus docetaxel was moderate
in extensively pretreated oesophageal cancer patients. Never-
theless, the response and survival data were better than the ones
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Figure 1 Kaplan–Meier survival for patients with progressive disease
during chemotherapy (n¼16) compared to those who achieved disease
stabilisation (stable disease or partial response, n¼8).
Table 2 Toxicity of weekly irinotecan plus docetaxel chemotherapy
Grade 3/4
Toxicity N (%)
Neutropenia 2 (8.3%)
Asthenia 5 (20.8%)
Diarrhoea 3 (12.5%)
Nausea/emesis 2 (8.3%)
Constipation 1 (4.2%)
N¼Number of patients.
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suggest a palliative benefit for the subset of patients who achieve
disease stabilisation. Therefore, the search for less toxic and more
active combination chemotherapy regimens in pretreated oeso-
phageal cancer remains justified within clinical trials.
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